Ligand appoints Jason Haas to Board of Directors, effective June 29, 2022

LIGAND PHARMACEUTICALS INC

Jason Haas appointed to Board and Audit Committee; brings 30+ years healthcare investment banking experience.
Haas currently CFO of Syros Pharmaceuticals; previously Co-Head Americas Healthcare Banking at Barclays.
Received 1,750 RSUs and options for 5,907 shares at $88.52, vesting over three years.
Chairman Kozarich cites Haas' 10+ years as Ligand financial advisor; appointment ahead of OmniAb spin-off.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jason Haas

Director

LGND · LIGAND PHARMACEUTICALS INC

Effective: 2022-06-29
Filed: June 29, 2022, 7:59 PM ET

Effective as of June 29, 2022, the Board of Directors of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Jason Haas to the Company’s Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jason Haas was appointed as Director at LIGAND PHARMACEUTICALS INC.

Action: appointed
Role: Director

Exact text from the filing

Effective as of June 29, 2022, the Board of Directors of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Jason Haas to the Company’s Board of Directors.

View on SEC.gov

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000886163-22-000097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.